The Acute Respiratory Distress Syndrome (ARDS) market is projected to grow steadily at a 3.8% CAGR through 2036, driven by rising ARDS cases and the development of innovative therapies like MultiStem, ExoFlo, and ThyrOxy. The US leads the market with the largest treatment size, and no FDA-approved ARDS-specific drugs currently exist, making mechanical ventilation the primary treatment. Emerging therapies in clinical trials could transform treatment standards and improve outcomes, signaling significant market and medical advancements ahead.
The Maryland Blockchain Association announced five new high-profile speakers for its 2026 Summer Conference, scheduled for July 13-17 at Capitol Technology University. The speakers include Bermuda's Premier E. David Burt, blockchain co-inventor Dr. W...
The Vancouver Fraser Port Authority awarded 29 terminals, tenants, and marine operators with Blue Circle Awards for their environmental leadership in reducing emissions, underwater noise, and conserving energy. Key initiatives include electrification...
Microsoft has advanced its quantum computing goals by replacing aluminum with lead in its Majorana 2 prototype, improving qubit stability and lifetime up to 20 seconds or more. This change enhances protection against cosmic disturbances, potentially ...
SpaceX plans to go public with an IPO priced at $135 per share, aiming to raise $75 billion and valuing the company at $1.75 trillion. The funds will support expansion in AI, Starlink satellite network, and new ventures like solar-powered space data ...
Johnson Controls International plc announced a quarterly dividend of $0.40 per share, payable on July 10, 2026, to shareholders recorded by June 15, 2026. The company, known for its leadership in thermal management and energy efficiency, has maintain...
